Mr. Rashid Bux reports

BIOMARK DIAGNOSTICS ANNOUNCES PUBLICATION OF PEER-REVIEWED VALIDATION OF MACHINE LEARNING MODELS FOR LUNG CANCER DETECTION IN FRONTIERS IN ONCOLOGY

Biomark Diagnostics Inc.'s long-term investment in integrating artificial intelligence and machine learning into metabolomic profiling has achieved a major milestone. As the global health care investment community is focused on the transformative power of AI at the J.P. Morgan Healthcare Conference, Biomark has received this week notification that its research regarding a machine-learning-driven predictive model for lung cancer detection has been accepted for publication in the prestigious, peer-reviewed journal Frontiers in Oncology.

The accepted article, titled "Translational impact of machine learning-driven predictive modeling with pathway-based plasma metabolomic biomarkers for lung cancer detection," represents a successful realization of Biomark's strategy to utilize advanced computational tools to enhance diagnostic precision. This achievement validates the company's past capital allocation toward sophisticated AI infrastructure and confirms the scientific rigour of its metabolic pathway analysis. By moving beyond traditional biomarker identification and utilizing pathway-level data, Biomark has demonstrated a more comprehensive way to interpret the metabolic signatures of early-stage lung cancer.

This research was made possible through a strategic collaboration with Dr. Maria Vaida and her team at the Harrisburg University of Science and Technology. Biomark is proud to highlight that the work led by Dr. Vaida has been recognized for its high quality and its significant contribution to the field of oncology. The publication describes the use of pathway-based features from the human metabolome database and explores the mechanistic drivers of cancer through interpretability tools such as SHAP analysis. This methodological approach allows for a deeper understanding of how specific metabolic pathways, such as those involved in nutrient processing and tumour growth, contribute to diagnostic models. The partnership with Harrisburg University has been instrumental in bridging the gap between complex data science and clinical application, ensuring that Biomark's technological foundation is built upon peer-reviewed, world-class scientific inquiry.

"The acceptance of our work in Frontiers in Oncology is a pivotal moment for Biomark as it provides third party validation of the investments we have made in AI and machine learning over the past several years," said Rashid Ahmed Bux, president and chief executive officer of Biomark. "At a time when the health care industry is increasingly looking for proof of concept in AI applications, this publication confirms that our collaborative work with Harrisburg University meets the highest standards of scientific excellence. We have successfully demonstrated that integrating machine learning with metabolomics is not just a theoretical pursuit, but a validated methodology that provides deep insights into the metabolic complexities of lung cancer."

The full paper is expected to be published later this month and will be made available through Biomark's website. This milestone reinforces the company's commitment to scientific transparency and its position at the intersection of oncology, metabolomics and advanced data science.

About Biomark Diagnostics Inc.

Biomark is a leading developer of liquid biopsy tests for the early detection of cancer that leverages the power of metabolomics and machine learning algorithms. The company's proprietary technology utilizes a simple blood draw to detect the presence of cancer-associated biomarkers, enabling earlier diagnosis and improved patient outcomes. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. Biomark is committed to developing innovative and accessible diagnostic solutions to address unmet medical needs in oncology.

We seek Safe Harbor.